Jeffrey W. Sherman, MD, FACP, is CMO and EVP at Horizon Therapeutics. Jeff has more than 30 years of biopharmaceutical industry experience at IDM Pharma, Takeda Global Research and Development, NeoPharm, Searle/Pharmacia, and Squibb/Bristol-Myers Squibb. He, a Past Chairperson of the Board of Directors of DIA, has served as DIA Annual Meeting Chair, received the DIA Outstanding Service Award, and served as DIA liaison to the FDA Clinical Trial Transformation Initiative (CTTI) Steering Committee, as well is an inaugural DIA Fellow. Jeff is also a member of the Global Genes Medical and Scientific Advisory Board and serves on the Board of Advisors of the Center for Information and Study on Clinical Research Participation (CISCRP).

Prof Sir Martin Landray is CEO of Protas, a non-profit company that focuses on advancing the design and delivery of highly efficient randomized trials of treatments for major health conditions. He is Professor of Medicine & Epidemiology at Oxford Population Health and has over 20 years’ experience leading large, randomized trials particularly in common cardiometabolic and kidney disease. He co-leads the RECOVERY trial, the world's largest and most successful trial of treatments for COVID-19, estimated to have prevented over 1 million deaths worldwide. He is a global thought leader in clinical trial policy and regulation, and led the Good Clinical Trials Collaborative. In June 2021, he was knighted for services to public health and science.

Ann Meeker-O’Connell is the Director of FDA’s Office of Clinical Policy in the Office of the Commissioner. In this role, she leads an organization that develops and implements cross-cutting policy related to clinical development and research ethics. Ms. Meeker-O’Connell has more than 20 years of experience in medical product development in government, academic, and industry settings, including prior FDA service as the Acting Director of the Division of Good Clinical Practice Compliance in CDER. She earned an MS in Pharmacology and was an NIH Integrated Toxicology Fellow at Duke University.

Dr. Pamela Tenaerts, currently serving as Medable's Chief Scientific Officer, is a respected advocate for clinical trial innovation. At Duke University, she previously led the Clinical Trials Transformation Initiative, improving efficiency and the quality of trials. With over three decades in conducting and researching clinical trials, her focus on patient engagement and evidence-based approaches has been notable. A board member at MedStar Research Institute, and an active member of the Drug Forum of the National Academies of Science, she holds an MD from the Catholic University of Leuven and an MBA from the University of South Florida.